🇺🇸 FDA
Patent

US 11324820

Methods for the treatment of subjects having a hepatitis b virus (HBV) infection

granted A61KA61K2039/5256A61K2039/545

Quick answer

US patent 11324820 (Methods for the treatment of subjects having a hepatitis b virus (HBV) infection) held by Alnylam Pharmaceuticals, Inc. expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
34
CPC classes
A61K, A61K2039/5256, A61K2039/545, A61K2039/55555, A61K2039/55561